Health-care companies ticked down as a retreat from one of the leading 2021 sectors continued.

Johnson & Johnson shares rose slightly after posting robust fourth-quarter sales growth. The health-care conglomerate finished 2021 with its strongest quarter to date for Covid-19 vaccine sales, contributing to year-over-year revenue growth across the company as it prepares to separate its consumer-health unit.

Covid-19 deaths in the U.S. have reached the highest level since early last year, rising to 2188 on Monday, reflecting the toll taken by the Omicron variant and rising case counts.


Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

01-25-22 1640ET